GSK Upbeat On RSV Vaccines, Hepatitis B Therapy
Walmsley Flags Future Growth Drivers
Executive Summary
GlaxoSmithKline's executive team outlined the progress the company is making against COVID-19, lupus nephritis, ovarian cancer and multiple myeloma.
You may also be interested in...
GSK's Growth Drivers And Cost Containment Offset Pandemic Impact
GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.
GSK To Address Multiple Myeloma With First-In-Class Blenrep In EU
The European Commission’s approval of GlaxoSmithKline’s Blenrep is one of the first major fruits of a refocused pipeline and development strategy at the big pharma company.
EU Fast-Track Loss For GSK's Dostarlimab
GSK’s potential endometrial cancer treatment dostarlimab is one of two products to revert to standard review timelines in recent weeks.